Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Anemia and chemotherapy].

Isabelle Ray-Coquard1, Thomas Bachelot, Catherine Sebban

  • 1Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon.

Bulletin Du Cancer
|July 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The French multicentric molecular analysis platforms and personalized medicine trials MOST, MOST Plus and MEGAMOST.

Acta oncologica (Stockholm, Sweden)·2024
Same author

Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.

Leukemia·2024
Same author

Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium.

International journal of cancer·2024
Same author

Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.

Leukemia·2024
Same author

Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations.

JAMA network open·2024
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles

Anemia is a frequent complication in cancer patients, often worsened by chemotherapy toxicity. Managing this condition is crucial for improving patient quality of life and treatment outcomes.

Area of Science:

  • Oncology
  • Hematology

Context:

  • Anemia is a common complication in cancer patient management.
  • Defined as decreased erythrocyte mass, typically assessed by hemoglobin levels.
  • Thresholds for anemia vary by sex and age (13 g/dl men, 11.5 g/dl women).

Purpose:

  • To investigate, quantify, prevent, and treat anemia in cancer patients.
  • To address anemia resulting from chemotherapy toxicity and inflammatory etiology.
  • To explore therapeutic strategies for anemia management.

Summary:

  • Anemia in cancer patients stems from nutritional factors, cancer pathology, and treatment side effects.
  • Chemotherapy toxicity exacerbates pre-existing anemia through multifactorial physiopathology.
  • Anemia significantly impacts quality of life, causing physical and social consequences.

Related Experiment Videos

Impact:

  • Highlights the need for effective anemia management in oncology.
  • Anemia necessitates specific treatments like blood transfusions or recombinant erythropoietin.
  • Addressing anemia can improve overall patient well-being and treatment adherence.